I2o Therapeutics develops oral formulations of long-acting GLP-1 receptor agonists and other peptide therapies to treat cardio-renal-metabolic diseases. Their approach aims to provide safer and more effective treatment options for patients with these complex conditions.
Funding
$53.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cardio-renal-metabolic diseases often require frequent injections of GLP-1 receptor agonists and other peptide therapies, leading to adherence challenges and suboptimal therapeutic outcomes. Current treatment options may also present safety concerns or limited efficacy for managing these complex conditions.
Solution
I2o Therapeutics is developing oral formulations of long-acting GLP-1 receptor agonists and other peptide therapies, aiming to provide safer, more effective, and convenient treatment options for patients with cardio-renal-metabolic diseases. Their "4D" approach focuses on de-risked, data-rich, differentiated, and documented FTO & IP assets. By transforming injectable peptides into oral medications, I2o Therapeutics seeks to improve patient compliance and overall disease management.
Target Audience
The primary target audience includes patients with cardio-renal-metabolic diseases, as well as healthcare providers specializing in these conditions.
Features
- Oral formulations of long-acting GLP-1 receptor agonists
- Oral formulations of long-acting Amylin agonists
- Oral formulations of long-acting PYY
- Oral formulations of long-acting Glucagon
- Focus on cardio-renal-metabolic diseases
- "4D" approach: De-Risked, Data Rich, Differentiated, Documented FTO & IP